The Use of FlowMet-R Technology to Predict Wound Healing in CLI Patients in a Wound Care Center Setting

Sponsor
Stanford University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05455554
Collaborator
Medtronic Endovascular (Industry), National Heart, Lung, and Blood Institute (NHLBI) (NIH)
100
1
16.2
6.2

Study Details

Study Description

Brief Summary

Single-institution, prospective nonrandomized pilot study of critical limb ischemia patients with planned lower extremity revascularization will undergo Flowmet-D measurements in a wound care center setting to determine threshold values associated with wound healing and amputation. A subset of patients will undergo hyperbaric oxygen therapy and will have Flowmet-D measurements to determine those who respond best to therapy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Flowmet-D
  • Diagnostic Test: ABI

Detailed Description

A single-institution, prospective nonrandomized pilot study will be conducted at Stanford Hospital and the Stanford Advanced Wound Care Center (AWCC). Patients with CLTI by WIfI criteria (ABI or toe pressures) and a concomitant non-healing lower extremity wound will be recruited. Inclusion criteria will include CLTI, at least one active lower extremity wound and planned lower extremity revascularization. ABI/TBIs will be recorded preintervention, post intervention and at one and three month intervals. Intraprocedural characteristics including the number and location of vessels revascularized, patent runoff vessels pre and post procedure, pedal arch anatomy and presence of angiographic "blush" to wound will be documented.

Post-operatively, patients will be followed at the AWCC where they will receive standard of care wound management including offloading, regular debridement, infection and edema management. FlowMet-R perfusion values will be obtained prerevascularization, immediately post revascularization as well as weekly at each follow up AWCC visit for a total of up to 6 months or until wound healing.Wound size will be recorded.

Patients who undergo hyperbaric oxygen therapy (at the discretion of AWCC surgeon) will have perfusion values performed before and after hyperbaric oxygen therapy sessions 1, 2, 10, 20, 30 and 40. Hyperbaric oxygen therapy will be conducted 5 days a week for duration of 90 minutes. Patients who undergo other advanced wound care treatments such as stem cell therapies or skin substitutes will also received FlowMet-R prior to and after treatment. Primary outcomes will be wound healing defined as complete skin epithelialization, wound improvement rate, major and minor amputations as well as need for repeat revascularization.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Use of FlowMet-R Technology to Predict Wound Healing in Critical Limb Ischemia (CLI) Patients in a Wound Care Center Setting
Actual Study Start Date :
Apr 27, 2022
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
CLI (Critical Limb Ischemia)

CLI cohort is a population of individuals with CLI, at least one active lower extremity wound and planned lower extremity revascularization. CLI cohort patients will receive Flowmet-D measurements in addition to standard of care therapy following intervention.

Diagnostic Test: Flowmet-D
Flowmet-D is a non-invasive device that measures blood flow.

Diagnostic Test: ABI
ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.

HBO (Hyperbaric Oxygen)

HBO cohort is a subset of the CLI cohort who will undergo hyperbaric oxygen therapy in the post-operative setting who will receive Flowmet-D measurements before and after their therapy.

Diagnostic Test: Flowmet-D
Flowmet-D is a non-invasive device that measures blood flow.

Diagnostic Test: ABI
ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.

Outcome Measures

Primary Outcome Measures

  1. Wound Healing [6 months]

    Wound Healing, defined as complete skin epithelialization, will be associated with Flowmet-D measurements.

  2. Wound Improvement [6 months]

    Wound Improvement, defined as improvement in wound size, will be associated with Flowmet-D values.

  3. Major Amputation [6 months]

    Major amputation, defined as amputation above the ankle joint, will be associated with Flowmet-D values.

  4. Minor Amputation [6 months]

    Minor amputation, defined as amputation below the ankle joint, will be associated with Flowmet-D values.

  5. Repeat Revascularization [6 months]

    Repeat Revascularization, defined as unplanned repeat lower extremity revascularization, will be monitored.

Secondary Outcome Measures

  1. Response to Hyperbaric Oxygen Therapy [6 months]

    Response to Hyperbaric Oxygen Therapy, will be defined as improved perfusion (improved Flowmet-D value) following therapy

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
CLI Cohort:
  • CLI by WIfI criteria (ABI or toe pressures)

  • Non-healing lower extremity wound

  • Planned lower extremity revascularization

  • Able to provide informed consent

  • Able to comply with study procedures

HBO Cohort:
  • All of the above

  • Enrolled in HBO therapy post revascularization (at the discretion of the provider)

Exclusion Criteria:
  • Under 30

  • Wound not suitable for FlowMet-D probe attachment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford Hospital Stanford California United States 94061

Sponsors and Collaborators

  • Stanford University
  • Medtronic Endovascular
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Venita Chandra, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Venita Chandra, Clinical Associate Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT05455554
Other Study ID Numbers:
  • 62133
  • 5R38HL143615-02
First Posted:
Jul 13, 2022
Last Update Posted:
Jul 13, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2022